Abstract
Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Current Drug Therapy
Title: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Volume: 6 Issue: 4
Author(s): Rajashree Hirlekar, Harshal Garse and Vilasrao Kadam
Affiliation:
Keywords: Poor solubility, bioavailability, solid lipid nanoparticles, nanostructured lipid carriers, characterization, stability, cholesterol, lipid dispersion, cold homogenization techniques, Triglycerides
Abstract: Solid lipid nanoparticles (SLN) were developed at the beginning of the 1990s as an alternative carrier system to emulsions, liposomes and polymeric nanoparticles. SLN are defined as aqueous colloidal carrier systems in the size range of 50-1000nm made up of solid lipid matrix. SLN combine advantages of the traditional systems but avoid some of their major disadvantages. They exhibit major advantages such as modulated release, improved bioavailability, protection of chemically labile molecules, cost effective excipients, improved drug incorporation and wide application spectrum. As a novel type of lipid nanoparticles with solid matrix, the nanostructured lipid carriers (NLC) are presented which overcomes the problems associated with SLN such as expulsion of drug from the matrix over the period of time. This paper presents an overview about the selection of the ingredients, different ways of production, drug incorporation and release, characterization of quality and structure, sterilization, storage, stability and applications of SLN & NLC dispersions.
Export Options
About this article
Cite this article as:
Hirlekar Rajashree, Garse Harshal and Kadam Vilasrao, Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review, Current Drug Therapy 2011; 6 (4) . https://dx.doi.org/10.2174/157488511798109637
DOI https://dx.doi.org/10.2174/157488511798109637 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry Crosstalk Between DNA and Histones: Tet’s New Role in Embryonic Stem Cells
Current Genomics Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Towards Isozyme-Selective HDAC Inhibitors For Interrogating Disease
Current Topics in Medicinal Chemistry Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry The Protease of Human T-Cell Leukemia Virus Type-1 is a Potential Therapeutic Target
Current Pharmaceutical Design Role of Infrared Spectroscopy and Imaging in Cancer Diagnosis
Current Medicinal Chemistry Human Hematopoietic Stem Cells in Gene Therapy: Pre-Clinical and Clinical Issues
Current Gene Therapy Regulation of the Immune Response by Natural IgM: Lessons from Warm Autoimmune Hemolytic Anemia
Current Pharmaceutical Design Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Current Drug Safety Membrane Tyrosine Kinase Receptors Kit and FLT3 are an Important Targets for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Novel Drug Targets in Malaria Parasite with Potential to Yield Antimalarial Drugs with Long Useful Therapeutic Lives
Current Pharmaceutical Design Therapeutic Nucleic Acids
Recent Patents on Regenerative Medicine The DDX3 Subfamily of the DEAD Box Helicases: Divergent Roles as Unveiled by Studying Different Organisms and In Vitro Assays
Current Medicinal Chemistry